Novel Transdermal Formulation for Treatment of Type 2 Diabetes - PowerPoint PPT Presentation

Novel Transdermal Formulation for Treatment of Type 2 Diabetes Reducta Biosciences • We have invented the synthetic steroid Fluasterone, a modified DHEA derivative • Fluasterone mimics the properties of DHEA (Dehydroepiandrosterone) • DHEA produces marked anti-diabetic, anti- inflammatory, anti-obesity and anti-cancer effects in mice and rats • Fluasterone works through unique anti- glucocorticoid and anti-inflammatory mechanisms

Major Potential Advantages of Fluasterone • Fluasterone works through unique anti-glucocorticoid and anti-inflammatory mechanisms • Applied topically – no needles • Lowered fasting plasma glucose levels in pre-diabetics • Lowered triglyceride levels in hyperglyceridimic patients • Both preclinical studies and human epidemiological findings suggest Fluasterone may reduce the incidence of cardiovascular disease in type 2 diabetics • Since cardiovascular disease is the number 1 cause of morbidity and mortality in type 2 diabetics, and none of the current anti-diabetic drugs have been shown to reduce this disease, Fluasterone has great potential promise over existing drugs